Patent · US Active

CD70 combination therapy

US11530271B2 · kind B2 · utility

1Cited by

28References

24Claims

0Family size

Assignee

argenx BV · BE

Inventors

Luc Van Rompaey · Mechelen, BE
Mahan Moshir · Wondelgem, BE
Tim Delahaye · Zwijnaarde, BE
Piotr Zabrocki · Zwijnaarde, BE

Key dates

Filing date	Jan 16, 2019
Grant date	Dec 20, 2022
Priority date	—
Expiry date	Oct 28, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/IL1RAP and CD47.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.